Short answers, pulled from the story.
The company officially changed its name to Cencora in August 2023 and began trading under the ticker symbol COR on the New York Stock Exchange. This rebranding followed years of growth as one of the largest pharmaceutical organizations globally.
David Yost served as the chief executive officer of AmeriSource Health Corporation before the deal and continued leading the combined entity afterward. Steven Collis replaced David Yost as CEO in July 2011.
Cencora bought 85% of Retina Consultants of America for roughly $4.4 billion on the 2nd of January 2025. This acquisition represents the most recent major deal undertaken by the American healthcare company.
AmerisourceBergen, McKesson, Cardinal Health, and Johnson & Johnson agreed to pay $26 billion to resolve claims from all but five states in January 2022. Had litigation proceeded to court, these companies faced potential penalties reaching up to $95 billion total.
AmerisourceBergen agreed to pay $625 million settling civil fraud allegations involving repackaged drugs and unapproved medications in October 2018. A subsequent agreement added another $260 million payment bringing the total settlement amount to $885 million.